Santhera Pharmaceuticals (OTCMKTS:SPHDF) Given Neutral Rating at Credit Suisse Group

Santhera Pharmaceuticals (OTCMKTS:SPHDF)‘s stock had its “neutral” rating reaffirmed by analysts at Credit Suisse Group in a report issued on Wednesday, The Fly reports.

Santhera Pharmaceuticals stock remained flat at $$2.75 during midday trading on Wednesday. Santhera Pharmaceuticals has a 12-month low of $2.62 and a 12-month high of $10.00. The stock has a 50 day moving average of $2.98 and a 200-day moving average of $3.34.

Santhera Pharmaceuticals Company Profile

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age.

Featured Article: Trading signals using Bollinger bands

The Fly

Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.